Press Release: InVivo Therapeutics Announces Webcast for Annual Shareholders Meeting to Be Held on May 23rd

CAMBRIDGE, Mass.----InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company will be conducting a webcast of the Annual Shareholders Meeting scheduled for Thursday, May 23, 2013 at 10:00 a.m. Eastern Daylight Time at the offices of Greenberg Traurig, LLP at One International Place, Boston, MA 02110.

The webcast can be accessed by interested shareholders and other parties at https://viavid.webcasts.com/starthere.jsp?ei=1017369. The meeting will also be accessible by telephone in listen-only mode. From the US, please dial 1-877-941-2068; from outside the US, please dial 1-480-629-9712. All participants should reference Conference ID 4620317. Slides from the meeting will be available to those viewing the webcast, and a replay of the webcast including presentation slides will also be available under the Investor Relations section of the InVivo Therapeutics website within 24 hours.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit http://www.invivotherapeutics.com.

Safe Harbor Statement

Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, and the Company intends that such statements are subject to the safe harbor created thereby. These statements include, but are not limited to, those relating to the expected approval of the FDA to conduct human clinical trials for the Company’s products, the expected commencement date of any approved human clinical trials, the expected size of the pilot study, the expectation that the scaffold product will be regulated under a HDE pathway, and the expected acceleration of commercialization of the Company’s products resulting therefrom. These forward-looking statements are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to obtain FDA approval to conduct human clinical trials; whether the human clinical trials produce acceptable results; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the year ended December 31, 2012 and subsequent filings with the SEC.

Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The Company undertakes no obligation and expressly disclaims any duty to update such statements.

Contacts

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Director, Investor Relations
bluque@invivotherapeutics.com

St. Joseph's unveils $15.5 million makeover plans

St. Joseph’s Hospital on Savannah’s southside will undergo a $15 million renovation beginning Monday that will ready the iconic 43-year-old structure for the future.

“It’s an extreme makeover,” Paul P. Hinchey, St. Joseph’s/Candler president and CEO, said in announcing the plan on Wednesday. “This is a big, big project. … We wanted to have a structure that would last another 50 years.”

The system’s plan calls for $11 million in exterior work and $4 million for 220 patient rooms slated for the makeover.

Minimal interference for patients or hospital services is anticipated during the makeover, Hinchey said.

When the 21-month project is completed, the hospital will “be really something to look at,” he said, comparing it to the Jepson Center for the Arts downtown and the Nancy N. and J.C. Lewis Cancer and Research Pavilion on DeRenne Avenue.

The seven-story, 305-bed hospital on a 28-acre tract opened in 1970 under Sister Mary Cornile Dulohery, Sister of Mercy who headed the hospital from 1960-82, and who decided a new facility was needed to replace the original St. Joseph’s at Taylor and Habersham streets after 94 years.,,,,

http://savannahnow.com/news/2013-05-16/st-josephs-unveils-155-million-makeover-plans#.UZW0laLvvIc